StockNews.com Begins Coverage on Tonix Pharmaceuticals (NASDAQ:TNXP)

Equities research analysts at StockNews.com started coverage on shares of Tonix Pharmaceuticals (NASDAQ:TNXP) in a research note issued to investors on Sunday. The firm set a “hold” rating on the stock.

Tonix Pharmaceuticals Price Performance

TNXP opened at $0.19 on Friday. Tonix Pharmaceuticals has a one year low of $0.12 and a one year high of $12.48. The company has a debt-to-equity ratio of 0.07, a current ratio of 3.33 and a quick ratio of 2.81. The stock has a market capitalization of $36.42 million, a P/E ratio of 0.00 and a beta of 2.07. The company’s 50 day simple moving average is $0.30 and its 200-day simple moving average is $0.27.

Tonix Pharmaceuticals (NASDAQ:TNXP) last posted its earnings results on Tuesday, November 12th. The company reported ($0.23) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.03) by $1.80. Tonix Pharmaceuticals had a negative return on equity of 163.95% and a negative net margin of 1,197.86%. The business had revenue of $2.82 million for the quarter, compared to analyst estimates of $2.63 million. Sell-side analysts anticipate that Tonix Pharmaceuticals will post -17.63 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Tonix Pharmaceuticals

A hedge fund recently bought a new stake in Tonix Pharmaceuticals stock. PFG Investments LLC acquired a new stake in shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund acquired 218,003 shares of the company’s stock, valued at approximately $72,000. PFG Investments LLC owned 0.12% of Tonix Pharmaceuticals at the end of the most recent quarter. 82.26% of the stock is currently owned by institutional investors and hedge funds.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.